QLGN: Qualigen Therapeutics, Inc. Stock

by  •  • Comments Off on QLGN: Qualigen Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1.95
Enterprise Value ($M) 2.85
Book Value ($M) -2.10
Book Value / Share -0.33
Price / Book -0.93
NCAV ($M) -2.97
NCAV / Share -0.47
Price / NCAV -0.66

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -0.84
Return on Equity (ROE) -2.16

Liquidity (mrq)
Quick Ratio 0.28
Current Ratio 0.28

Balance Sheet (mrq) ($M)
Current Assets 1.17
Assets 2.03
Liabilities 4.14
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -11.30
Net Income -13.42
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -10.30
Cash from Investing 4.22
Cash from Financing -0.55

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-08 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-07-07 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1)

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-15 18,503 132,963 13.92
2024-05-14 67,296 10,727 627.35
2024-05-13 34,067 118,349 28.79
2024-05-10 6,490 45,956 14.12

(click for more detail)

Similar Companies
PTIX – Protagenic Therapeutics, Inc. PTPI – Petros Pharmaceuticals, Inc.
PULM – Pulmatrix, Inc. QLI – Qilian International Holding Group Limited
RENB – Renovaro Inc.


Financial data and stock pages provided by
Fintel.io